Humira In 2023: The $17bn Biosimilar Opportunity
Landmark LOE Looms In US; Several Adalimumab Launches Expected Throughout Year
• By David Wallace
Humira’s loss of US exclusivity in 2023 represents the biggest opportunity yet for biosimilars • Source: Shutterstock 
